| 摘要 |
<p>The invention is directed to altering the N-terminal amino acid sequence of butyrophilin to eliminate an autoimmune response, diagnostics for identifying individuals susceptible to an autoimmune response triggered by ingesting butyrophilin, and genetically engineered mammals capable of expressing butyrophilin void of amino acid sequences that elicit a cross-reactive immune response to myelin oligodendrocyte glycoprotein.</p> |
